Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came from animal models, epidemiological studies or mechanistic pathway analyses. Now, a team at the University of Manchester has uncovered direct mechanistic and clinical evidence that PR antagonists can reprogram the breast tissue microenvironment, suggesting a novel avenue for reducing breast cancer risk in women.

At the AACR-NCI-ORTC conference, researchers from Dewpoint Therapeutics Inc. presented advances in targeting MYC condensates, revealing a potential breakthrough strategy for treating cancers driven by MYC – a well-established oncogenic driver that is frequently overexpressed or amplified across a range of human cancers.